๐Ÿงช Beta โ€” BiohacksAI is under active development. Data and features may change.
B
BiohacksAI
Evidence-Based Biohacking
BetaPatent Pending

N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide vs cyclohexyl

Mechanistic comparison of N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide [Supplementary Concept] and cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester [Supplementary Concept] based on molecular target overlap from BindingDB and ChEMBL binding affinity data.

4
Shared Targets
15%
Jaccard Similarity
17%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.

Evidence Comparison

N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide [Supplementary Concept]
โ€”
Evidence Score
8
PubMed Studies
View full profile โ†’
cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester [Supplementary Concept]
โ€”
Evidence Score
100
PubMed Studies
View full profile โ†’

Target Overlap

N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide and cyclohexyl share 4 molecular targets based on binding affinity data from BindingDB (Kd/IC50 โ‰ค 10 ยตM) and ChEMBL. A Jaccard index of 0.154 means 15% of the combined target set is bound by both compounds. The IDF-weighted score of 0.174 accounts for non-specific binding to metabolic enzymes.

Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.

Frequently Asked Questions

What do N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide and cyclohexyl have in common?
N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide and cyclohexyl share 4 molecular targets with a Jaccard similarity of 15%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide and cyclohexyl be combined?
N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide and cyclohexyl share 4 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide or cyclohexyl?
In the BiohacksAI corpus: N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide has 8 PubMed-indexed studies, cyclohexyl has 100 studies.

Related Comparisons

Similar to N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide

N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide vs Canagliflozin5 targetsN-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide vs casin5 targetsN-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide vs cinacalcet8 targetsN-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide vs darapladib7 targetsN-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide vs Fluvastatin4 targets

Similar to cyclohexyl

cyclohexyl vs urb5 targetscyclohexyl vs palmidrol4 targetscyclohexyl vs obeticholic3 targetscyclohexyl vs 52 targetscyclohexyl vs Probenecid2 targets
View full N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide profile โ†’View full cyclohexyl profile โ†’Browse all substances โ†’